Moderna | Financial Buzz

Biotechnology Healthcare Investing News Market News Technology The Market Buzz

Moderna Announces mRNA-1345 Phase 3 Results

Danny Abramov01/18/2023

16438

Moderna, Inc. (NASDAQ: MRNA) has announced positive data from its ConquerRSV Phase 3 trial of mRNA-1345, an investigational mRNA vaccine that targets respiratory syncytial virus in older adults. Following...

Investing News Life Style Market News Medical Use Pharmaceutical Products Technology The Market Buzz Your Environment

Modena, Merk Cancer Vaccine Reduced Melanoma Recurrence by 44%

Rebecca Urena12/13/2022

16426

Moderna (NASDAQ: MRNA) has developed an experimental personalized melanoma vaccine, which along with Merck & Co’s blockbuster immunotherapy Keytruda cut the risk of the skin cancer’s reappearance or death...

Investing News Life Style Market News Medical Use Pharmaceutical Products The Market Buzz Your Environment

FDA Authorizes Covid Omicron Vaccines for Children as Young as 6 Months

Rebecca Urena12/08/202212/08/2022

16470

The Food and Drug Administration recently authorized Covid shots, that target the omicron variant, for children as young as 6 months old. Eligibility varies depending on if the children...

Tag: Moderna

Moderna Announces mRNA-1345 Phase 3 Results

Modena, Merk Cancer Vaccine Reduced Melanoma Recurrence by 44%

FDA Authorizes Covid Omicron Vaccines for Children as Young as 6 Months

ABOUT US

Tweets